نتایج جستجو برای: hdaci

تعداد نتایج: 694  

2012
Maria Beconi Omar Aziz Kim Matthews Lara Moumné Catherine O’Connell Dawn Yates Steven Clifton Hannah Pett Julie Vann Lynsey Crowley Alan F. Haughan Donna L. Smith Ben Woodman Gillian P. Bates Fred Brookfield Roland W. Bürli George McAllister Celia Dominguez Ignacio Munoz-Sanjuan Vahri Beaumont

Histone deacetylase (HDAC) inhibitors have received considerable attention as potential therapeutics for a variety of cancers and neurological disorders. Recent publications on a class of pimelic diphenylamide HDAC inhibitors have highlighted their promise in the treatment of the neurodegenerative diseases Friedreich's ataxia and Huntington's disease, based on efficacy in cell and mouse models....

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2008
Jinhai Fan Jennifer Stanfield Yi Guo Jose A Karam Eugene Frenkel Xiankai Sun Jer-Tsong Hsieh

PURPOSE Romidepsin (FK228, depsipeptide, FR901228), a unique cyclic depsipeptide with a histone deacetylase inhibitor (HDACI) activity, is a potential cancer therapeutic agent and currently under clinical trials for several types of cancer. For bladder cancer, romidepsin seems to be a potent antitumor agent from our recent study. In this study, we further delineate a new agent that can enhance ...

2017
Sofia Rivera Céline Leteur Frédérique Mégnin Frédéric Law Isabelle Martins Ioana Kloos Stéphane Depil Nazanine Modjtahedi Jean Luc Perfettini Christophe Hennequin Eric Deutsch

Despite prominent role of radiotherapy in lung cancer management, there is an urgent need for strategies increasing therapeutic efficacy. Reversible epigenetic changes are promising targets for combination strategies using HDAC inhibitors (HDACi).Here we evaluated on two NSCLC cell lines, the antitumor effect of abexinostat, a novel pan HDACi combined with irradiation in vitro in normoxia and h...

Journal: :Nutrition and cancer 2012
Mohammed O Altonsy Tito N Habib Simon C Andrews

The health benefits of garlic have been proven by epidemiological and experimental studies. Diallyl disulphide (DADS), the major organosulfur compound found in garlic oil, is known to lower the incidence of breast cancer both in vitro and in vivo. The studies reported here demonstrate that DADS induces apoptosis in the MCF-7 breast-cancer cell line through interfering with cell-cycle growth pha...

2016
Madhura G. Kelkar Kalimuthu Senthilkumar Smita Jadhav Sudeep Gupta Beyong-Cheol Ahn Abhijit De

The aberrant expression of human sodium iodide symporter (NIS) in breast cancer (BC) has raised the possibility of using targeted radioiodide therapy. Here we investigate modulation of endogenous, functional NIS expression by histone deacetylase inhibitors (HDACi) in vitro and in vivo. Luciferase reporter based initial screening of six different HDACi shows 2-10 fold enhancement of NIS promoter...

2011
Luca A. Petruccelli Daphné Dupéré-Richer Filippa Pettersson Hélène Retrouvey Sophia Skoulikas Wilson H. Miller

Histone deacetylase inhibitors (HDACi) are promising anti-cancer agents, however, their mechanisms of action remain unclear. In acute myeloid leukemia (AML) cells, HDACi have been reported to arrest growth and induce apoptosis. In this study, we elucidate details of the DNA damage induced by the HDACi vorinostat in AML cells. At clinically relevant concentrations, vorinostat induces double-stra...

Journal: :Molecular cancer therapeutics 2010
Ruman Rahman Teresa Osteso-Ibanez Robert A Hirst Jane Levesley John-Paul Kilday Siobhan Quinn Andrew Peet Chris O'Callaghan Beth Coyle Richard G Grundy

Aberrant epigenetic regulation of gene expression contributes to tumor initiation and progression. Studies from a plethora of hematologic and solid tumors support the use of histone deacetylase inhibitors (HDACi) as potent anticancer agents. However, the mechanism of HDACi action with respect to the temporal order of induced cellular events is unclear. The present study investigates the antican...

Journal: :Molecular pharmacology 2010
Keeming Chia Heather Beamish Kaneez Jafferi Brian Gabrielli

Histone deacetylase inhibitors (HDACis) are currently in trial or are in clinical use for the treatment of a number of tumor types. The clinical efficacy of HDACis can be partly attributed to the modulation of the cell cycle by the HDACis. Here, we have examined the effects of N-(2-aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide (MGCD0103), a class I-selective histone deacet...

2011
Valentina Zuco Michelandrea De Cesare Raffaella Cincinelli Raffaella Nannei Claudio Pisano Nadia Zaffaroni Franco Zunino

Preclinical studies support the therapeutic potential of histone deacetylases inhibitors (HDACi) in combination with taxanes. The efficacy of combination has been mainly ascribed to a cooperative effect on microtubule stabilization following tubulin acetylation. In the present study we investigated the effect of paclitaxel in combination with two novel HDACi, ST2782 or ST3595, able to induce p5...

2017
Young Jun Kim Sang Jun Park Na Rae Kim Hee Seung Chin

PURPOSE To evaluate the effects of valproic acid (VPA), a histone deacetylase inhibitor (HDACI), on the expression of hypoxia-inducible factor-1 alpha (HIF-1α) and vascular endothelial growth factor (VEGF) in human retinal Müller cells under hypoxic conditions. METHODS Chemical hypoxia was induced in human retinal Müller cells (MIO-M1) by treatment with increasing concentrations of cobalt(II)...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید